| Belantamab Mafodotin studied in …STUDIED_INderived66 of 66show fewer |
|---|
| → studied in | NCT05874193Phase 2 · withdrawn A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04876248Phase 2 · active not recruiting Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789303Phase 2 · recruiting Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05208307Phase 2 · recruiting Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06232044Phase 1/Phase 2 · suspended Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227311Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05145816Phase 1/Phase 2 · recruiting Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis · 66 trials list this drug (42 active) | — | — | AL Amyloidosis,Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05714839Phase 1/Phase 2 · recruiting A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07285239Phase 3 · recruiting Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05091372Phase 2 · recruiting Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680468Phase 2 · active not recruiting Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748689Phase 2 · not yet recruiting Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04617925Phase 2 · completed A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis · 66 trials list this drug (42 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07720843Phase 1 · not yet recruiting TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05556798Phase 1 · active not recruiting A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07224672Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis · 66 trials list this drug (42 active) | — | — | Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05847569Phase 2 · recruiting Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04162210Phase 3 · active not recruiting Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04398745Phase 1 · active not recruiting A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150104Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217119Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217184Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07614360Phase 2 · not yet recruiting Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637526not yet recruiting Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04643002Phase 1/Phase 2 · recruiting Isatuximab in Combination With Novel Agents in RRMM - Master Protocol · 66 trials list this drug (42 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150091Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04484623Phase 3 · active not recruiting Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06956170Phase 3 · active not recruiting All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05055063Phase 1 · recruiting A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609706Phase 1 · not yet recruiting A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05002816Phase 1/Phase 2 · active not recruiting Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05060627Phase 1/Phase 2 · active not recruiting Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126200Phase 1/Phase 2 · active not recruiting Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07084896Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05064358Phase 2 · completed Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246047Phase 3 · active not recruiting Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868654Phase 3 · active not recruiting China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868667Phase 3 · active not recruiting Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06679101Phase 3 · recruiting A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04676360Phase 2 · terminated Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma · 66 trials list this drug (42 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802356Phase 2 · active not recruiting Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05922501Phase 2 · recruiting Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Malignant Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04398680Phase 1 · withdrawn A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04091126Phase 1 · active not recruiting Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05065047Phase 1 · terminated Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03828292Phase 1 · completed An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05461209Phase 3 · withdrawn A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892264Phase 1 · terminated Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05833737terminated Corneal Findings in Patients Treated With Belantamab Mafodotin · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04177823Phase 1 · completed A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03544281Phase 1/Phase 2 · completed To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06655818Phase 1/Phase 2 · terminated Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05986682completed Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05117008Phase 2 · terminated Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05393024completed Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03848845Phase 1/Phase 2 · completed Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06160609Phase 1/Phase 2 · terminated Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04549363Phase 3 · terminated Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05280275Phase 1/Phase 2 · unknown A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible · 66 trials list this drug (42 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04808037Phase 1/Phase 2 · active not recruiting Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05573802Phase 1/Phase 2 · recruiting A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma · 66 trials list this drug (42 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05493618Phase 1/Phase 2 · withdrawn Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581875Phase 1/Phase 2 · not yet recruiting A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory · 66 trials list this drug (42 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05297240unknown Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain. · 66 trials list this drug (42 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02064387Phase 1 · completed Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 · 66 trials list this drug (42 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |